EGFR and lung adenocarcinoma: One study that examined PGVs in lung adenocarcinoma found them to occur at a comparable or slightly lower rate as TCGA at 2.5–4.5%, and also found that mutations most commonly occurred in ATM (50%), followed by TP53 (28.6%), BRCA2, EGFR, and PARK2, all (7.1%) [42].